• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

January 6, 2009 Approval Letter

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville MD 20852--1448

January 6, 2009

Gambro BCT, Inc.
Attention: Ms. Kathy Coressel
10811 West Collins Avenue
Lakewood, CO 80215

Re: BA070025/0

Dear Ms. Coressel:

Please refer to your abbreviated new drug application (ANDA) dated May 11, 2007 and received May 14, 2007, submitted under section 505(j)/pursuant to section 505(j)(2) of the Federal Food, Drug, and Cosmetic Act, for Anticoagulant Citrate Phosphate Dextrose Solution (CPD).

We acknowledge receipt of your submission dated July 16, 2008 and received July 17, 2008. Your submission of July 16, 2008 constituted a complete response to our December 21, 2007 Not Approvable letter.

We have completed our review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, this application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the draft labeling submitted on December 02, 2008. Marketing the products with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit the final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but not more than 30 days
after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved ANDA BA070025." Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with the requirements set forth under 21 CFR 314.80 and 314.81 for an approved NDA.

If you have any questions, please contact Heather Erdman, Regulatory Project Manager, at (301) 827-6182.

Sincerely,

-- signature --

Jay Epstein, M.D.
Director
Office of Blood Research and Review
Center for Biologics Evaluation and Research

 

Contact FDA

(800) 835-4709
(301) 827-1800
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

1401 Rockville Pike

Suite 200N/HFM-47

Rockville, MD 20852-1448